Optimizing Ventana Chromogenic Dual In-situ Hybridization for Mucinous Epithelial Ovarian Cancer

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2013 Dec 31

PMID 24373486

Citations 1

Authors

Xinyun Li

Sung-Hock Chew

Wen-Yee Chay

Soo-Kim Lim-Tan

Liang-Kee Goh

Affiliations

Soon will be listed here.

Abstract

Background: Dual in-situ hybridization (DISH) assay is a relatively new assay for evaluating Human Epidermal Growth Factor Receptor 2 (HER2) genomic amplification. Optimization protocol for the assay is not yet well established, especially for archival tissues. Although there is a recommended nominal protocol, it is not suited for formalin-fixed and paraffin-embedded (FFPE) samples that were archived for long periods.

Findings: In a study on local population of mucinous epithelial ovarian cancer, we developed a series of optimization protocols based on the age of samples to improve success of the DISH assay. A decision workflow was generated to facilitate individualization of further optimization protocols. The optimizations were evaluated on 92 whole tissue sections of FFPE mucinous ovarian tumors dating from 1990 to 2011. Overall, 79 samples were successfully assayed for DISH using the series of optimization protocols. We found samples older than 1 year required further optimization beyond the nominal protocol recommended. Thirteen samples were not further assayed after first DISH assay due to inadequately preserved nuclear morphology with no ISH signals throughout the tissue section.

Conclusion: The study revealed age of samples and storage conditions were major factors in successful DISH assays. Samples that were ten years or less in age, and archived in-house were successfully optimized, whereas older samples, which were also archived off-site, have a higher frequency of unsuccessful optimizations. The study provides practical and important guidelines for the new DISH assay which can facilitate successful HER2 evaluation in ovarian cancers and possibly other cancers as well.

Citing Articles

Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update.

Todorovic-Rakovic N Methods Mol Biol. 2021; 2318:313-320.

PMID: 34019299 DOI: 10.1007/978-1-0716-1476-1_17.

References

Huang R, Chen G, Matsumura N, Lai H, Mori S, Li J . Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics. 2012; 5:47. PMC: 3567940. DOI: 10.1186/1755-8794-5-47. View

Mayr D, Kanitz V, Amann G, Engel J, Burges A, Lohrs U . HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology. 2006; 48(2):149-56. DOI: 10.1111/j.1365-2559.2005.02306.x. View

Koh Y, Lee H, Lee J, Kang J, Gong G . Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol. 2011; 24(6):794-800. DOI: 10.1038/modpathol.2011.9. View

Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H . Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2012; 229(1):111-20. DOI: 10.1002/path.4088. View

Gruver A, Peerwani Z, Tubbs R . Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol. 2010; 63(3):210-9. PMC: 2921277. DOI: 10.1136/jcp.2009.062760. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2009; 131(1):18-43. DOI: 10.5858/2007-131-18-ASOCCO. View

Harrison M, Jameson C, Gore M . Mucinous ovarian cancer. Int J Gynecol Cancer. 2007; 18(2):209-14. DOI: 10.1111/j.1525-1438.2007.01022.x. View

Schweiger M, Kerick M, Timmermann B, Albrecht M, Borodina T, Parkhomchuk D . Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One. 2009; 4(5):e5548. PMC: 2678265. DOI: 10.1371/journal.pone.0005548. View

McAlpine J, Wiegand K, Vang R, Ronnett B, Adamiak A, Kobel M . HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009; 9:433. PMC: 2803495. DOI: 10.1186/1471-2407-9-433. View

10.

Chay W, Chew S, Ong W, Busmanis I, Li X, Thung S . HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 2013; 8(4):e61565. PMC: 3631219. DOI: 10.1371/journal.pone.0061565. View

11.

Yildiz-Aktas I, Dabbs D, Bhargava R . The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol. 2012; 25(8):1098-105. DOI: 10.1038/modpathol.2012.59. View

12.

von Ahlfen S, Missel A, Bendrat K, Schlumpberger M . Determinants of RNA quality from FFPE samples. PLoS One. 2007; 2(12):e1261. PMC: 2092395. DOI: 10.1371/journal.pone.0001261. View

13.

Yan B, Choo S, Mulyadi P, Srivastava S, Ong C, Yong K . Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol. 2011; 64(12):1097-101. DOI: 10.1136/jclinpath-2011-200082. View

14.

De Marzo A, Fedor H, Gage W, Rubin M . Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum Pathol. 2002; 33(7):756-60. DOI: 10.1053/hupa.2002.126187. View

15.

Dressler L, Berry D, Broadwater G, Cowan D, Cox K, Griffin S . Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005; 23(19):4287-97. DOI: 10.1200/JCO.2005.11.012. View

16.

Faratian D, Graham A, Rae F, Thomas J . Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology. 2009; 54(4):428-32. DOI: 10.1111/j.1365-2559.2009.03257.x. View

17.

Lam Shang Leen S, Singh N . Pathology of primary and metastatic mucinous ovarian neoplasms. J Clin Pathol. 2011; 65(7):591-5. DOI: 10.1136/jclinpath-2011-200162. View

18.

Ng D, Koh D, Choo S, Ng V, Fu Q . Effect of storage conditions on the extraction of PCR-quality genomic DNA from saliva. Clin Chim Acta. 2004; 343(1-2):191-4. DOI: 10.1016/j.cccn.2004.01.013. View

19.

Nitta H, Kelly B, Padilla M, Wick N, Brunhoeber P, Bai I . A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012; 7:60. PMC: 3487810. DOI: 10.1186/1746-1596-7-60. View